Login to Your Account



Clinic Roundup


Friday, May 13, 2011
Oxigene Inc., of South San Francisco, announced that investigators at the University of Florida initiated a Phase I study of OXi4503 for the treatment of patients with acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS). The company said that the open-label, dose-escalating study is sponsored in part by the Leukemia & Lymphoma Society's Therapy Acceleration Program and will be conducted in patients with relapsed or refractory AML or MDS to evaluate the safety profile, maximum tolerated dose and biologic activity of OXi4503

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription